Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical firm headquartered in Carlsbad, California, dedicated to innovating targeted therapies that address tumor resistance mechanisms in cancer. By leveraging its proprietary drug discovery platform, Tyra aims to enhance therapeutic efficacy and patient outcomes in oncology. The company’s focus on the development of novel compounds positions it strategically within the competitive landscape of cancer therapeutics, aiming to deliver transformative treatments for patients facing daunting resistance challenges.